Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 12 September 2017, 23:06 HKT/SGT
Share:
    

Source: Eisai
Eisai and Mamorio to Jointly Launch "Me-Mamorio" Tracking Tool to Support People with Dementia and Seniors Going Out

TOKYO, Sept 12, 2017 - (JCN Newswire) - Eisai Co., Ltd. and MAMORIO, Inc. have announced that the MeMAMORIO(1) tracking tool to support people with dementia and seniors going out will be launched in Japan on September 13.

Me-MAMORIO is a small tag that utilizes the short-range wireless Bluetooth(2) communication standard. It is light weight and shaped like a round button. To make it easier for people with dementia and seniors to carry it around with them, it can be sewn into a jacket or hat or attached to a bag or wallet. When people with dementia and seniors carrying the Me-MAMORIO tag pass close to people in the community who have the corresponding application installed on their smartphones, or to fixed receivers which have been set up in stations and other areas, Me-MAMORIO's positional data is automatically sent to a server. Family members or related care workers can then confirm the positional data with their smartphones. Additionally, to prepare for emergency situations such as the sudden injury or illness of a Me-MAMORIO user, services such as a 24-hour hotline for emergency medical advice and a medical institution information service will be provided in collaboration with the Tokio Marine Group.

According to statistics provided by the Ministry of Internal Affairs and Communications, by the year 2025, in which the baby boomer generation will be aged 75 and over, there will be 36.57 million seniors aged 65 or over in Japan, accounting for 30% of the overall population. Additionally, the Ministry of Health, Labour and Welfare estimates that by the year 2025, one in five people aged 65 or over will suffer from dementia, increasing the number of dementia sufferers to approximately 7 million. Furthermore, according to statistics provided by the National Police Agency, of the missing persons reported to the police in 2016, 15,432 were people with dementia. This number has been increasing year after year since they began tracking it in 2012.

Eisai and Mamorio entered into an agreement to jointly develop Me-MAMORIO in July 2016, and with the cooperation of various stakeholders including local governments and community residents, conducted demonstrations aiming for implementation. The demonstrations revealed that modifying the shape and weight of tags to make them easier to carry and improving the accuracy of positional data were necessary to support people with dementia and seniors going out freely. Additionally, it was determined that in conjunction with the usage of Me-MAMORIO, it would be important to create a supportive environment, including a human network. Since 2008, Eisai has been collaborating with various stakeholders including local governments, healthcare professionals and care workers to build communities where people with dementia can live safely and with peace of mind. This includes disease awareness activities and interprofessional collaboration such as between healthcare professionals and care workers. With the use of Me-MAMORIO as the premise, Eisai aims to support the creation of community environments where residents can help watch over people with dementia and seniors to support them going out.

MAMORIO Inc. already possesses one of Japan's largest smartphone application networks, which was built up through sales of MAMORIO (another type of tag that uses the same IoT tag technology as MeMAMORIO to track lost items), and fixed receivers which have been set up in "MAMORIO Spots", such as stations and department stories, to pick up positional data from tags. These will also be usable for the rollout of Me-MAMORIO.

In addition to spreading Me-MAMORIO, Eisai and MAMORIO will work together to establish an environment where the community as a whole can look out for people with dementia and seniors, and realize a society where people with dementia and seniors can preserve their individuality and freely go out in the town they're used to living in.


About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Sept 12, 2017 23:06 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech, HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 31, 2018 14:13 HKT/SGT
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in China to CY Biotech
July 31, 2018 10:27 HKT/SGT
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA
July 26, 2018 10:34 HKT/SGT
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at AAIC 2018
July 26, 2018 08:01 HKT/SGT
Eisai and Biogen Present Detailed Results from Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at AAIC 2018
July 19, 2018 09:38 HKT/SGT
Latest Data on Eisai's Alzheimer's Disease / Dementia Pipeline to be Presented at Alzheimer's Association International Conference (AAIC) 2018
July 18, 2018 11:04 HKT/SGT
Eisai: Positive Topline Results Obtained from Large-Scale Cardiovascular Outcomes Trial of Anti-Obesity Agent BELVIQ
July 11, 2018 15:32 HKT/SGT
Eisai: Oral Antifungal Agent Nailin Capsules 100mg to be Launched in Japan
July 10, 2018 10:14 HKT/SGT
Eisai: Oral Presentation on Phase II Clinical Study Results of BAN2401 to be Presented at Alzheimer's Association International Conference (AAIC) 2018
July 9, 2018 14:07 HKT/SGT
Eisai: Results from Two Phase 3 Clinical Trials of Chronic Constipation Treatment "GOOFICE 5mg Tablet" Published in The Lancet Gastroenterology & Hepatology
July 6, 2018 09:31 HKT/SGT
Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 At 18 Months
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: